Azor (Amlodipine Bes/Olmesartan Med) Patent Expiration, LOE Window & CMS Spending
Azor (Amlodipine Bes/Olmesartan Med) by Cosette: Off-Patent Genericized (AB Competition), 9 AB generics, $2.9M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Cosette |
| FDA Application & Pathway | N022100 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 9 |
| 2024 CMS Total Public Spend | $2.9M |
| 2024 Medicare Part D Spend | $2.9M |
| 2024 Medicaid Spend | $17K |
| Reported Wholesale Price Change (CA SB 17) | 12 WAC filings (max 32.9% 2-yr change) |